Oncology

Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival

July 28, 2009
Eric Raymond

Eric Raymond

Treatment of advanced pancreatic islet cell tumors with sunitinib has doubled progression-free survival in patients whose options have been very limited up to now, according to French researchers reporting their phase III randomized study findings at the World Congress on Gastrointestinal Cancer in Barcelona (24-27 June, 2009; ABSTRACT: 0-0013). Eric Raymond from Beaujon University Hospital, Villejuif, France, gave Peter Goodwin his clinical interpretation of the findings.

Download this interview

Add podcast to iTunes

Similar Interviews

  • ASCO Audio Journal of Oncology – August 1st 2006

    • John Neoptolemos

  • ASCO Annual Meeting Daily News Podcasts – June 5th, 2007

    • Aimery de Gramont Robert Mayer MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage

  • Natalizumab Risks and Benefits in Multiple Sclerosis

    • Chris Polman, Free University of Amsterdam Abstract N Engl J Med 2006;345:899 Despite fears that natalizumab - which reduces progression in some

    Post a comment